Financial Disclosure and Conflict of Interest

Part of Principal Investigator (PI) Training: Signatures and What They Attest.

About 4 minutes. Free, in your language, no account needed.

Why this matters

A physician investigator sits at an uncomfortable intersection. You are paid, directly or through your institution, to enroll participants into a study whose result may affect a company's revenue — and you are also the person those participants trust to tell them whether joining is a good idea for them.

That tension is not misconduct. It is structural, it is normal, and it is managed by disclosure rather than denial. What turns it into misconduct is concealment.

What has to be disclosed, and to whom

Three separate audiences ask, for three different reasons.

The regulator. In the United States, 21 CFR part 54 requires sponsors submitting a marketing application to disclose certain financial interests of clinical investigators — arrangements where compensation could be affected by the study outcome, significant payments of other sorts, proprietary interest in the product, and significant equity interest in the sponsor. In practice you will be asked to complete a financial disclosure form at start-up and to update it during the study and for a period after it ends. That updating obligation is the one investigators most often miss: acquiring shares in the sponsor two years into a trial is disclosable.

The ethics committee. IRBs and IECs routinely ask about investigator and institutional financial interests as part of their review. Requirements vary by jurisdiction and by committee.

The participant. Consent should describe the trial honestly, including sources of funding (§2.8.10). A participant is entitled to know who is paying for the study they are being invited into.

Payment that becomes undue influence

Section 1.2.8 addresses payments to participants: the IRB or IEC reviews both the amount and the method of payment to ensure that neither presents problems of coercion or undue influence. The principle is that compensation should reflect burden — time, travel, inconvenience — rather than function as an inducement to accept risk.

The same logic applies upward, to you. Per-participant payments are normal and legitimate; they fund the work. A payment structure that rewards volume without regard to eligibility is a structure that puts pressure on the one judgment that must stay clean: whether this particular person should be in this particular trial. If your budget contains an enrollment bonus, be conscious of it at the moment you review eligibility, and consider disclosing it to your ethics committee.

Equipoise, and the therapeutic misconception's cousin

Beyond money there is a subtler conflict, and physicians feel it more than anyone else in the trial.

The ethical basis for randomizing your own patient is equipoise — genuine uncertainty about which arm is better. If you are privately convinced the investigational product is superior, you have a problem: you cannot honestly present randomization as a fair choice, and your enthusiasm will reach the participant whether you intend it or not.

The Declaration of Helsinki is explicit that the participant's interests take precedence over the interests of science and society, and requires conflicts of interest to be declared. When you no longer hold equipoise for a particular patient, the answer is to stop offering them the trial — not to consent them anyway and hope.

Managing it in practice

• Complete the disclosure form honestly at start-up, and diarize a review of it annually and at study close.
• Report changes when they happen — new equity, new consultancy, new advisory board with the sponsor.
• Tell participants who funds the study, in the consent discussion and not only in the form.
• Keep the person who reviews eligibility insulated from recruitment targets, even if that person is you and the insulation is only a habit of asking "would I enroll this patient if the target were already met?"
• If in doubt, disclose. Disclosure has never made a trial harder to defend.

Key takeaways

• Financial conflict is structural, not shameful; concealment is what makes it misconduct.
• 21 CFR part 54 is a United States requirement, includes an ongoing update obligation, and is not ICH.
• §1.2.8 requires ethics review of the amount and method of participant payment to guard against undue influence; the same reasoning applies to enrollment incentives for the site.
• Equipoise is the ethical basis for randomization. When you lose it for a given patient, stop offering them the trial.